Thrombocytopenia with quetiapine: two case reports, one with positive rechallenge

Rev Bras Psiquiatr 2015;37:351
doi:10.1590/1516-4446-2015-1766

Antipsychotic-induced thrombocytopenia is generally rare, but seems to occur more frequently with quetiapine. Accordingly, the relative risk of thrombocytopenia can be described as very rare with loxapine and clozapine ($< 0.01\%$), uncommon with risperidone ($\geqslant 0.1\%$, $< 1\%$), but very common with quetiapine ($\geqslant 10\%$). However, very few cases are reported in the literature,[1-4] with one published case of idiopathic thrombocytopenic purpura,[1] and it remains unclear whether rechallenge may be considered.

Patient no. 1 was a 78-year-old male hospitalized for depressive syndrome and treated with mirtazapine 45 mg/day, valpromide 1,000 mg/day, and oxazepam 30 mg/day. Quetiapine was added at 50 mg/day, while mirtazapine was reduced to 30 mg/day. Laboratory tests carried out the following day and 5 days after the start of treatment with quetiapine revealed platelet counts of 100,000/mm^3 and 56,000/mm^3 respectively. Two further measurements were obtained, 8 days and 28 days after discontinuing treatment with quetiapine, showing higher platelet levels of 85,000/mm^3 and 120,000/mm^3 respectively.

Patient no. 2 was a 72-year-old female hospitalized for personality disorders with hallucinations and treated with aripiprazole 15 mg/day, clonazepam 0.6 mg/day, valproic acid 1,500 mg/day, furosemide 40 mg/day, lisinopril 20 mg/day, nebivolol 5 mg/day, and amlodipine 10 mg/day. During her hospitalization, aripiprazole was stopped and quetiapine 50 mg/day was introduced. Tests performed 3 months after initiating treatment with quetiapine were notable for a platelet count of 107,000/mm^3. Six days later, a second test was carried out, and the platelet count was down to 95,000/mm^3. Treatment with quetiapine was suspended for 3 days, following which the platelet count went back up to 120,000/mm^3. The psychiatrist reintroduced quetiapine and scheduled a control platelet test 5 days later, which showed a decrease to 84,000/mm^3. In view of this positive rechallenge, quetiapine was discontinued definitively. Fifteen days after quetiapine discontinuation, the platelet count was 123,000/mm^3.

In both situations, no other clinical or iatrogenic parameter seemed to account for the onset of thrombocytopenia. To our knowledge, the second patient described herein is the first case of quetiapine-induced thrombocytopenia with positive rechallenge to be in the literature.

Alexandre Lalli,[1] Bruno Michel,[2] Sébastien Georget,[1] Catherine Bouillot,[3] Anne Mangin,[1] Hervé Javelot[4]
[1]*Service Pharmacie, Centre Psychothérapique de Nancy - Laxou (CPN Laxou), Laxou, France.* [2]*Service Pharmacie, Centres Hospitaliers et Universitaires, Strasbourg, France.* [3]*Service de soins Archambault, CPN Laxou, Laxou, France.* [4]*Service Pharmacie, Etablissement Public de Santé Alsace Nord, Brumath, France.*

Submitted Jun 24 2015, accepted Jul 11 2015.

Disclosure

The authors report no conflicts of interest.

References

1 Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother. 2005;39:1346-8.
2 Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics. 2007;48:530-1.
3 Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:158-63.
4 Handoo I, Perales M, Klaus N, Khan AY. Thrombocytopenia secondary to the use of quetiapine. J Child Adolesc Psychopharmacol. 2010;20:453-5.

NBOMe: a new dangerous drug similar to LSD

Rev Bras Psiquiatr. 2015;37:351-352
doi:10.1590/1516-4446-2015-1774

A 26-year-old Brazilian woman with a history of club drug use, in addition to cannabis and alcohol use, was referred to a clinic for substance abuse treatment after being found unconscious by security guards at a street party. Upon admission, the patient reported that she started using psychoactive substances when she was 16 years old. At that occasion, she ran away from home and started living with a friend who was a synthetic drug dealer. Motivated by the availability of drugs at a low price, and being in close contact with drug users, she started to increasingly use drugs such as 3,4-methylenedioxymethamphetamine (MDMA). Increased consumption led to increased tolerance, and as a result she started to look for substances with more powerful and longer-lasting effects. Eight months before admission, she started using NBOMe (25I-NBOMe) weekly at electronic music parties, having as many as four blotters per week. While intoxicated, the patient reported engaging in moral and sexual exposure, including being nude and masturbating in public and having unprotected sex with several different partners. After these events, she would not remember anything about the actions, locations or individuals with whom she had been. As she started treatment, she was tested for HIV and had a positive result. A diagnosis of other hallucinogen use disorder – NBOMe (304.50 – F16.20 severe) and conduct disorder (312.82 – F16.20 moderate) was established according to DSM-5 and ICD-11.

There is a growing international concern over the manufacturing and distribution of synthetic analogs of controlled substances as an attempt to circumvent drug